ProPhase Labs, Inc.: Form 10-K for the period ended Dec 31, 2016
Filed with the SEC on Feb 24, 2017 and accepted by EDGAR at Feb 24, 2017, 21:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2016-01-01 to 2016-12-31 | $21.0m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months2016-01-01 to 2016-12-31 | $10.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2016-01-01 to 2016-12-31 | $10.1m | us-gaap:GrossProfit |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $575.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2016-01-01 to 2016-12-31 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2016-01-01 to 2016-12-31 | $213.0k | us-gaap:InterestExpense |
| Net income | 12 months2016-01-01 to 2016-12-31 | −$2.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | −$472.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $651.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-12-31 | $441.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $9.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $12.8m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $6.8m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2016-12-31 | $6.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-17-001890. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.